Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association..
With the increase in large multimodal cohorts and high-throughput technologies, the potential for discovering novel biomarkers is no longer limited by data set size. Artificial intelligence (AI) and machine learning approaches have been developed to detect novel biomarkers and interactions in complex data sets. We discuss exemplar uses and evaluate current applications and limitations of AI to discover novel biomarkers. Remaining challenges include a lack of diversity in the data sets available, the sheer complexity of investigating interactions, the invasiveness and cost of some biomarkers, and poor reporting in some studies. Overcoming these challenges will involve collecting data from underrepresented populations, developing more powerful AI approaches, validating the use of noninvasive biomarkers, and adhering to reporting guidelines. By harnessing rich multimodal data through AI approaches and international collaborative innovation, we are well positioned to identify clinically useful biomarkers that are accurate, generalizable, unbiased, and acceptable in clinical practice. HIGHLIGHTS: Artificial intelligence and machine learning approaches may accelerate dementia biomarker discovery. Remaining challenges include data set suitability due to size and bias in cohort selection. Multimodal data, diverse data sets, improved machine learning approaches, real-world validation, and interdisciplinary collaboration are required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Alzheimer's & dementia : the journal of the Alzheimer's Association - 19(2023), 12 vom: 15. Dez., Seite 5860-5871 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Winchester, Laura M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AI |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 06.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/alz.13390 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361518390 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361518390 | ||
| 003 | DE-627 | ||
| 005 | 20240206231910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alz.13390 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM361518390 | ||
| 035 | |a (NLM)37654029 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Winchester, Laura M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. | ||
| 520 | |a With the increase in large multimodal cohorts and high-throughput technologies, the potential for discovering novel biomarkers is no longer limited by data set size. Artificial intelligence (AI) and machine learning approaches have been developed to detect novel biomarkers and interactions in complex data sets. We discuss exemplar uses and evaluate current applications and limitations of AI to discover novel biomarkers. Remaining challenges include a lack of diversity in the data sets available, the sheer complexity of investigating interactions, the invasiveness and cost of some biomarkers, and poor reporting in some studies. Overcoming these challenges will involve collecting data from underrepresented populations, developing more powerful AI approaches, validating the use of noninvasive biomarkers, and adhering to reporting guidelines. By harnessing rich multimodal data through AI approaches and international collaborative innovation, we are well positioned to identify clinically useful biomarkers that are accurate, generalizable, unbiased, and acceptable in clinical practice. HIGHLIGHTS: Artificial intelligence and machine learning approaches may accelerate dementia biomarker discovery. Remaining challenges include data set suitability due to size and bias in cohort selection. Multimodal data, diverse data sets, improved machine learning approaches, real-world validation, and interdisciplinary collaboration are required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a AI | |
| 650 | 4 | |a biomarker discovery | |
| 650 | 4 | |a dementia | |
| 650 | 4 | |a machine learning | |
| 650 | 4 | |a multimodal | |
| 700 | 1 | |a Harshfield, Eric L |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Liu |e verfasserin |4 aut | |
| 700 | 1 | |a Badhwar, AmanPreet |e verfasserin |4 aut | |
| 700 | 1 | |a Khleifat, Ahmad Al |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Dehsarvi, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Lengyel, Imre |e verfasserin |4 aut | |
| 700 | 1 | |a Lourida, Ilianna |e verfasserin |4 aut | |
| 700 | 1 | |a Madan, Christopher R |e verfasserin |4 aut | |
| 700 | 1 | |a Marzi, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a Proitsi, Petroula |e verfasserin |4 aut | |
| 700 | 1 | |a Rajkumar, Anto P |e verfasserin |4 aut | |
| 700 | 1 | |a Rittman, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Silajdžić, Edina |e verfasserin |4 aut | |
| 700 | 1 | |a Tamburin, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Ranson, Janice M |e verfasserin |4 aut | |
| 700 | 1 | |a Llewellyn, David J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's & dementia : the journal of the Alzheimer's Association |d 2005 |g 19(2023), 12 vom: 15. Dez., Seite 5860-5871 |w (DE-627)NLM168942356 |x 1552-5279 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:12 |g day:15 |g month:12 |g pages:5860-5871 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alz.13390 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 12 |b 15 |c 12 |h 5860-5871 | ||